Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.61 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20337895 | 0.99 | LOXL2 (0.60) | LOXL2HTR6MAP2K7ERBB2DRD2 | |
| SCHEMBL18362163 | 0.88 | LOXL2 (0.61) | LOXL2HTR6 | |
| SCHEMBL18361824 | 0.85 | LOXL2 (0.64) | LOXL2HTR6MPO | |
| SCHEMBL18362032 | 0.84 | LOXL2 (0.59) | LOXL2HTR6 | |
| SCHEMBL18361822 | 0.84 | LOXL2 (0.74) | LOXL2 | |
| Trifluoroacetic Acid SCHEMBL20337875 | 0.84 | LOXL2 (0.56) | LOXL2HTR6 | |
| SCHEMBL18049191 | 0.83 | LOXL2 (0.52) | LOXL2HTR6MPOKLKB1KLK1 | |
| SCHEMBL18361807 | 0.83 | LOXL2 (0.65) | LOXL2ERBB2 | |
| Hydrochloric Acid SCHEMBL18049098 | 0.83 | LOXL2 (0.52) | LOXL2HTR6KLKB1KLK1 | |
| Acetic Acid SCHEMBL20337861 | 0.82 | LOXL2 (0.66) | LOXL2MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | claimed |
| EP-3510404-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | Pharmakea, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA INC (US) | 2018-07-05 | — | — | US | disclosed |
| WO-2018048928-A1 | CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF | PHARMAKEA, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2017003862-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| US-9109103-B2 | Functionalized polymer, rubber composition and pneumatic tire | THE GOODYEAR TIRE & RUBBER COMPANY (US) | 2015-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186755-A1 | LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | LOXL2 1/4885HTR6 2732/4885MAP2K7 4203/4885 |
| US-20190192697-A1 | CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF | LOXL2, LOXL1, LOXL3 | LOXL2 1/4885HTR6 2899/4885MAP2K7 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.